{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:22:56Z","timestamp":1791332576515,"version":"4.3.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3805,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1002\/hep.20672","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T23:48:57Z","timestamp":1111708137000},"page":"753-760","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":204,"title":["Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy\u2020"],"prefix":"10.1097","volume":"41","author":[{"given":"Edward D.","family":"Javor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine K.","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Arioglu","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex M.","family":"DePaoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahalya","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Gorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20250325","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0002-9343(79)90740-X","article-title":"Fatty liver hepatitis and cirrhosis in obese patients","volume":"67","author":"Adler","year":"1979","journal-title":"Am J Med"},{"key":"R2-12-20250325","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(99)00163-4","article-title":"Non\u2010alcoholic steatohepatitis: another disease of affluence","volume":"353","author":"James","year":"1999","journal-title":"Lancet"},{"key":"R3-12-20250325","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-12-20250325","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"R5-12-20250325","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"R6-12-20250325","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/gut.50.5.585","article-title":"Non\u2010alcoholic steatohepatitis (NASH): where are we now and where are we going?","volume":"50","author":"Day","year":"2002","journal-title":"Gut"},{"key":"R7-12-20250325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI200422422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning","year":"2004","journal-title":"J Clin Invest"},{"key":"R8-12-20250325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2004-823098","article-title":"Nonalcoholic steatohepatitis","volume":"24","author":"Brunt","year":"2004","journal-title":"Semin Liver Dis"},{"key":"R9-12-20250325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.med.53.082901.104057","article-title":"Lipotoxic diseases","volume":"53","author":"Unger","year":"2002","journal-title":"Annu Rev Med"},{"key":"R10-12-20250325","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin\u2010replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-12-20250325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"R12-12-20250325","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00004424-199112000-00002","article-title":"Fatty liver: chemical shift phase\u2010difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans","volume":"26","author":"Mitchell","year":"1991","journal-title":"Invest Radiol"},{"key":"R13-12-20250325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0730-725X(96)00224-X","article-title":"Introduction of fast MR imaging in the assessment of hepatic steatosis","volume":"15","author":"Fishbein","year":"1997","journal-title":"Magn Reson Imaging"},{"key":"R14-12-20250325","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"HEPATOLOGy"},{"key":"R15-12-20250325","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"key":"R16-12-20250325","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"R17-12-20250325","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1210\/jc.2003-031952","article-title":"Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson\u2010Mendenhall syndrome","volume":"89","author":"Cochran","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-12-20250325","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.md.0000133625.73570.54","article-title":"Clinical course of genetic diseases of the insulin receptor (type A and Rabson\u2010Mendenhall syndromes): a 30\u2010year prospective","volume":"83","author":"Musso","year":"2004","journal-title":"Medicine (Baltimore"},{"key":"R19-12-20250325","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005792-200203000-00001","article-title":"Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28\u2010year perspective","volume":"81","author":"Arioglu","year":"2002","journal-title":"Medicine (Baltimore"},{"key":"R20-12-20250325","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1210\/endo.139.11.6308","article-title":"Characterization of expression of hypothalamic appetite\u2010regulating peptides in obese hyperleptinemic brown adipose tissue\u2010deficient (uncoupling protein\u2010promoter\u2010driven diphtheria toxin A) mice","volume":"139","author":"Tritos","year":"1998","journal-title":"Endocrinology"},{"key":"R21-12-20250325","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty\u2010acid oxidation by activating AMP\u2010activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature"},{"key":"R22-12-20250325","doi-asserted-by":"crossref","first-page":"11848","DOI":"10.1073\/pnas.182420899","article-title":"PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue","volume":"99","author":"Lee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-12-20250325","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz","year":"2004","journal-title":"J Clin Invest"},{"key":"R24-12-20250325","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1073\/pnas.0308258100","article-title":"Rapid transformation of white adipocytes into fat\u2010oxidizing machines","volume":"101","author":"Orci","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-12-20250325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0092-8674(00)80611-X","article-title":"Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC\u20101","volume":"98","author":"Wu","year":"1999","journal-title":"Cell"},{"key":"R26-12-20250325","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa031314","article-title":"Impaired mitochondrial activity in the insulin\u2010resistant offspring of patients with type 2 diabetes","volume":"350","author":"Petersen","year":"2004","journal-title":"N Engl J Med"},{"key":"R27-12-20250325","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1172\/JCI200113914","article-title":"Selective deletion of leptin receptor in neurons leads to obesity","volume":"108","author":"Cohen","year":"2001","journal-title":"J Clin Invest"},{"key":"R28-12-20250325","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","article-title":"The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies","volume":"42","author":"Adams","year":"2005","journal-title":"J Hepatol"},{"key":"R29-12-20250325","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","author":"Leclercq","year":"2002","journal-title":"J Hepatol"},{"key":"R30-12-20250325","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/jhep.2001.26518","article-title":"Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals","volume":"34","author":"Ikejima","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R31-12-20250325","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1111\/j.1572-0241.2003.08767.x","article-title":"Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?","volume":"98","author":"Chalasani","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R32-12-20250325","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00004836-200411000-00002","article-title":"The role of leptin in NAFLD: contender or pretender?","volume":"38","author":"Poordad","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R33-12-20250325","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jhep.2004.08.020","article-title":"Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease","volume":"41","author":"Angulo","year":"2004","journal-title":"J Hepatol"},{"key":"R34-12-20250325","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis","volume":"96","author":"Caldwell","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R35-12-20250325","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/diabetes.52.6.1364","article-title":"Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes","volume":"52","author":"Bajaj","year":"2003","journal-title":"Diabetes"},{"key":"R36-12-20250325","first-page":"1008","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR\u2010gamma ligand rosiglitazone","volume":"38","author":"Neuschwander\u2010Tetri","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R37-12-20250325","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid\u2010activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"R38-12-20250325","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1172\/JCI1235","article-title":"Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats","volume":"101","author":"Okuno","year":"1998","journal-title":"J Clin Invest"},{"key":"R39-12-20250325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"R40-12-20250325","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator\u2010activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J Biol Chem"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20672","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200504000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:04:11Z","timestamp":1743066251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200504000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20672","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}